Alembic Pharma Q2 Results: Net profit rises 12% to Rs 153 crore, revenue up 3%
The company reported Rs 133 crore in net profit in Q2FY23.
Revenues grew 3% to Rs.1648 crores in Q2FY25 compared to Rs 1595 crore last year.
The earnings before interest, tax, depreciation and amortization (EBITDA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 15.6% in Q2FY25.
The domestic formulation business that constitutes about 37% revenues rose 6% YoY to Rs 609 crore in Q2FY25. Alembic has a market share of 1.4% of the Indian pharma market and four brands with revenue of Rs 1 billion, according to IQVIA, September 2024 data. Around 13% of the product portfolio is under National List of Essential Medicine (NLEM) price control.
Stock Trading
Point & Figure Chart Mastery: A Comprehensive Trading Guide
By — Mukta Dhamankar, Full Time Trader, 15 Years Experience, Instructor
Stock Trading
Technical Analysis for Everyone — Technical Analysis Course
By — Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities
Stock Trading
Macroeconomics Made Easy: Online Certification Course
By — Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant
Stock Trading
Market 103: Mastering Trends with RMI and Techno-Funda Insights
By — Rohit Srivastava, Founder- Indiacharts.com
Stock Trading
Advanced Strategies in Stock Market Mastery
By — CA Raj K Agrawal, Chartered Accountant
Stock Trading
ROC Made Easy: Master Course for ROC Stock Indicator
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
Candlesticks Made Easy: Candlestick Pattern Course
By — elearnmarkets, Financial Education
